Damora Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
DMRA$24.07+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $257,624 | $14,175 |
| Prepaid expenses and other current assets | 2,799 | 2,664 |
| Total current assets | 260,423 | 16,839 |
| Operating lease right-of-use asset | 68 | 73 |
| Equipment, net | 36 | 57 |
| Other assets, noncurrent | — | 163 |
| Total assets | $260,527 | $17,132 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $444 | $377 |
| Accrued expenses and other current liabilities | 2,401 | 820 |
| Related party accounts payable and other current liabilities | 17,221 | — |
| Total current liabilities | 20,066 | 1,197 |
| Operating lease liabilities, noncurrent | 53 | 61 |
| Other liabilities, noncurrent | 28 | 43 |
| Total liabilities | 20,147 | 1,301 |
| Commitments and contingencies (Note 11) | ||
| Mezzanine equity | ||
| Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024; 159 shares issued and outstanding as of December 31, 2025 and 161 shares issued or outstanding as of December 31, 2024 | 1,341 | 1,360 |
| Stockholders’ equity | ||
| Series B non-voting convertible preferred stock, par value of $0.00001 per share; 16,366 shares authorized at December 31, 2025; 16,366 shares issued and outstanding as of December 31, 2025 and no shares issued or outstanding as of December 31, 2024 | 117,621 | — |
| Series C non-voting convertible preferred stock, par value of $0.00001 per share; 43,882 shares authorized at December 31, 2025; 43,882 shares issued and outstanding as of December 31, 2025 and no shares issued or outstanding as of December 31, 2024 | 297,291 | — |
| Common stock, par value of $0.00001 per share; 500,000,000 shares authorized at December 31, 2025 and 2024; 1,597,321 and 1,316,989 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — |
| Additional paid-in capital | 310,688 | 291,898 |
| Accumulated deficit | (487,363) | (277,524) |
| Accumulated other comprehensive income | 802 | 97 |
| Total stockholders’ equity | 240,380 | 15,831 |
| Total liabilities and stockholders’ equity | $260,527 | $17,132 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.